Pharmacogenomics of Platinum-Based Chemotherapy Response in Nsclc: A Genotyping Study and A Pooled Analysis

Juan Chen,Zhan Wang,Ting Zou,Jiajia Cui,Jiye Yin,Wei Zheng,Wuzhong Jiang,Honghao Zhou,Zhaoqian Liu

DOI: https://doi.org/10.18632/oncotarget.9688

2016-01-01

Oncotarget

Abstract:Published data showed inconsistent results about associations of extensively studied polymorphisms with platinum-based chemotherapy response. Our study aimed to provide reliable conclusions of these associations by detecting genotypes of the SNPs in a larger sample size and summarizing a comprehensive pooled analysis. 13 SNPs in 8 genes were genotyped in 1024 NSCLC patients by SequenomMassARRAY. 39 published studies and our study were included in meta-analysis. Patients with GA or GG genotypes of XRCC1 G1196 had better response than AA genotype carriers (Genotyping study: OR = 0.72, 95% CI: 0.53-0.96, P = 0.028; Meta-analysis: OR = 0.74, 95% CI: 0.62-0.89, P = 0.001). Patients carrying CT or TT genotypes of XRCC1 C580T could be more sensitive to platinum-based chemotherapy compared to patients with CC genotype (OR = 0.54, 95% CI: 0.37-0.80, P = 0.002). CC genotype of XRCC3 C18067T carriers showed more resistance to platinum-based chemotherapy when compared to those with CT or TT genotypes (OR = 0.69, 95% CI: 0.52-0.91, P = 0.009). Our study indicated that XRCC1 G1196A/ C580T and XRCC3 C18067T should be paid attention for personalized platinum-based chemotherapy in NSCLC patients.